Phosphoramide functionalized FeO nanoparticles (NPs) were synthesized by a three step procedure and its application for uranium extraction from different enviornmental matrices has been demonstrated. A maximum adsorption capacity of 95.2 mg of U/g of the sorbent has been achieved which is higher as compared to many reported magnetic NPs. pH dependent adsorption studies were performed at 1 ppm uranium concentrations which suggests more than 80% adsorption in pH range of 4-8 with maximum adsorption at pH 6. Interestingly this is the pH range of most naturally occurring water bodies suggesting the potential of this material to extract uranium from real environmental samples. Adsorption studies were carried out with tap water, drinking water and sea water and more than 90% uranium extraction was observed. Desorption studies were performed with different reagents suggesting that the material can be reused again. EXAFS studies have been carried out which suggests that the uranium binds with oxygens of three PO group at the surface of phosphoramide functionalized NPs and based on this, binding mode of uranium with the synthesized sorbent is proposed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhazmat.2019.121353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of CART Cell Therapy in Aggressive B-Cell Lymphomas Involving the Gastrointestinal Tract.
Cancer Rep (Hoboken)
January 2025
Department of Adult Lymphoma, Beijing Boren Hospital, Beijing, China.
Objective: Currently, chimeric antigen receptor T-cell (CART) therapy represents a highly effective approach for relapsed/refractory B-cell lymphomas. However, it also carries treatment-related risks. Limited data are available on the risks associated with CART therapy in patients with gastrointestinal involvement in B-cell lymphomas.
View Article and Find Full Text PDFCirculating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center.
Acta Med Indones
October 2024
1. Department of Hematology and Medical Oncology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia. 2. Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia..
Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and radiologic evaluation, diffuse large B-cell lymphoma (DLBCL) still carries high recurrence in clinical practice. This case series aims to assess the potential of circulating free RNA as a biomarker for evaluating therapeutic responses in DLBCL.
View Article and Find Full Text PDFEvaluation of treatment for diffuse large B-cell lymphoma using plasma D-dimer levels.
Sci Rep
January 2025
Department of Hematology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
It has been documented that D-dimer levels have potential utility as a measure of tumor activity in diffuse large B-cell lymphoma (DLBCL), however whether it can be used as a predictive marker of treatment outcome has not been established. This study means to retrospectively evaluate the role of D-dimer in prediction of treatment efficacy in patients with DLBCL. 151 patients with newly diagnosed DLBCL were enrolled.
View Article and Find Full Text PDFA Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer.
Curr Oncol
December 2024
Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Background: Anthracycline-taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC).
Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017.
Dual T cell depleted haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and anti-thymocyte globulin as a third salvage transplant for leukocyte adhesion deficiency with graft failure: a case report.
Front Immunol
January 2025
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: With recent advances in clinical practice, including the use of reduced-toxicity conditioning regimens and innovative approaches such as ex vivo TCRαβ/CD19 depletion of haploidentical donor stem cells or post-transplant cyclophosphamide (PTCY), hematopoietic stem cell transplantation (HSCT) has emerged as a curative treatment option for a growing population of patients with inborn errors of immunity (IEI). However, despite these promising developments, graft failure (GF) remains a significant concern associated with HSCT in these patients. Although a second HSCT is the only established salvage therapy for patients who experience GF, there are no uniform, standardized strategies for performing these second transplants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!